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mellitus in mice through activating AMPK
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Abstract
Background: Gestational diabetes mellitus (GDM) is a disease often manifests in mid to late pregnancy with
symptoms including hyperglycemia, insulin resistance and fetal mal-development. The C57BL/KsJ-Lepdb/+ (db/+)
mouse is a genetic GDM model that closely mimicked human GDM symptoms. Resveratrol (RV) is a naturally
existing compound that has been reported to exhibit beneficial effects in treating type-2 diabetes.
Methods: In this study, we investigated the effect of RV on the pregnant db/+ GDM mouse model, and the
underlying molecular mechanism.
Results: RV greatly improved glucose metabolism, insulin tolerance and reproductive outcome of the pregnant
db/+ females. Moreover, we found that RV relieved GDM symptoms through enhancing AMPK activation, which in
turn reduced production and activity of glucose-6-phosphatase in both pregnant db/+ females and their offspring.
Conclusions: Our findings further supported the potential therapeutic effect of RV on not only diabetes, but also
alleviating GDM.
Keywords: Resveratrol, Gestational diabetes mellitus, db/+ mouse model, AMP-activated protein kinase, Glucose-6-
phosphatase
Background
Gestational diabetes mellitus (GDM) is a condition typ-
ically caused by insufficient insulin production or signal-
ing in pregnant women [1]. Patients suffering from
GDM usually do not present any signs of diabetes prior
to pregnancy, and are commonly diagnosed during the
second trimester of pregnancy, with 3–5 % of women
even suffering long-term diabetes after pregnancy [2].
Apart from maternal diabetic symptoms, GDM also re-
sulted in abnormal fetal development [3]. The C57BL/
KsJ-Lepdb/+ (db/+) mouse, harboring a heterozygous mu-
tation in the leptin receptor gene Lepr [4], closely mim-
icked GDM symptoms observed in human patients. At
the non-pregnant state, they exhibited largely normal
glucose and insulin tolerance until gravidity [5, 6]. Dur-
ing pregnancy, the db/+ females presented typical GDM
symptoms including hyperglycemia, insulin resistance
and obesity. Fetal development was also adversely affected,
with increased body weight of offspring at birth [7, 8].
Resveratrol (Fig. 1a. 3,4,5-trihydroxy-trans-stilbene, RV)
is a naturally existing polyphenol that can be found in
grapes, cranberries and red wine, and increasing body of
studies have recently reported its role in the treatment of
diabetes in various animal models. In diabetic mouse
models, either from genetically deficient in insulin recep-
tor substrate 2 or streptozotocin-induced diabetes, RV
treatment restores peripheral insulin sensitivity in a sirt1-
independent manner [9]. However in streptozotocin-
induced diabetic rats, RV was found to regulate the sirt1
pathway and glucose transporters [10]. Using a similar
streptozotocin-induced diabetic rat model, Sadi et al. con-
ducted a series of studies, demonstrating that RV induced
differential gene expression in the liver that antago-
nized diabetic symptoms [11], while regulated oxida-
tive biomarkers and anti-oxidant enzymes in the brain
[12], and more importantly improved hepatic insulin
signaling and reduced inflammatory response [13].
Also in streptozotocin-induced diabetic rats, RV exerted
beneficial effects on the kidney through extenuating the
oxidative stress and down-regulation of receptor for ad-
vanced glycation end-products [14].
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Of particular relevance to our current study, RV was
found to attenuate high glucose-induced oxidative stress
and cardiomyocyte apoptosis through AMP-activated
protein kinase (AMPK) [15]. AMPK could be a potential
cross-species target of RV function in diabetes, because
a recent study employing the Japanese macaque high fat
dietary model, it was also found to stimulate AMPK ac-
tivation and transporter expression in the placenta [16].
The AMPK signaling pathway coordinates cell growth,
autophagy and metabolism [17]. Particularly in the liver,
AMPK activation reduces glucose production, by phos-
phorylating and suppressing the class IIa family of his-
tone deacetylases (HDACs), resulting in down-regulation
of gluconeogenesis genes such as glucose-6-phosphatase
(G6Pase) [18].
In this study, we applied RV on the db/+ genetic GDM
mouse model, aiming to investigate if RV could exhibit
similar functions on GDM as reported by previous
diabetes-related studies [15, 16]. By measuring serum glu-
cose and insulin levels before and during pregnancy, we
could evaluate the effect of RV on GDM-related symp-
toms. Furthermore we also examined states of AMPK ac-
tivation, in order to decipher the potential underlying
mechanism explaining the beneficial role of RV on GDM.
Methods
Animals and study design
Care and use of mice in this study abide the guidelines
and protocol approved by the Institutional Animal Care
and Use Committee of Shandong Provincial Hospital Af-
filiated to Shandong University. All efforts were exhausted
to minimize unnecessary suffering of experimental mice.
Six to eight weeks old C57BL/KsJ+/+ (wild type) and
C57BL/KsJdb/+ (db/+) mice were purchased from Jackson
Fig. 1 Effects of RV on glucose and insulin tolerance. a Chemical structure of resveratrol (RV). b and c Effects of RV on serum glucose (b) and
insulin (c) levels during intraperitoneal glucose tolerance test in non-pregnant wild type and db/+ mice. d and e Effects of RV on serum glucose
(d) and insulin (e) levels during intraperitoneal glucose tolerance test in pregnant wild type and db/+ mice on gestation day 10. f Effects of RV on
serum glucose level during intraperitoneal insulin tolerance test in pregnant wild type and db/+ mice on gestation day 10. Values represented
mean ± SEM (n = 18). *P < 0.01, #P < 0.05, db/+ pair-fed vs wild type and db/+ pair-fed + RV mice at the same time point
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Laboratories. Mice were housed in a room with controlled
temperature (22 ± 2 °C), humidity (40–60 %) and light
cycle (12/12 h light/dark). Mice were fed with the chow
diet (Harlan Teklad) consisted of 29 % protein, 47 %
carbohydrate and 17 % fat, and water. Female mice were
randomly divided into three experimental groups (n = 18
per group): wild type, ad libitum-fed; db/+ pair-fed, food
intake of the ad libitum-fed wild-type was measured daily,
and the same amount of food was pair-fed to db/+ mice;
db/+ pair-fed + RV, db/+ pair-fed mice were administered
by oral gavage with resveratrol (RV; Sigma-Aldrich), solu-
bilized in water, at the dose of 10 mg/kg body weight per
day, throughout the entire span of the study. Wild type
and db/+ pair-fed groups of mice were also orally gavaged
with water only daily, throughout the entire span of the
study, to serve as vehicle control. At 10–12 weeks of age,
female mice were individually mated with males of the
same genotype, and mating was confirmed by the pres-
ence of a copulatory plug the next morning, which was
designated gestation day (GD) 0. Since not all females
could become pregnant after mating, an initial number of
more than 18 females per group were used, and eventually
18 pregnant females were used in each experimental
group as described above.
Glucose tolerance test
Mice before pregnancy and on GD 10 were fasted for
6 h and injected intraperitoneally with glucose at 2 g/kg
body weight. Blood samples were collected from the tail
using capillary tubes at 0, 30 and 60 min after glucose
administration.
Insulin tolerance test
Mice on GD 10 were fasted 6 h and injected intraperito-
neally with insulin at 0.75 U/kg body weight. Blood sam-
ples were collected from the tail using capillary tubes at
0, 30 and 60 min after insulin administration.
Measurement of serum glucose, insulin and body weight
Serum glucose, insulin levels and body weight were mea-
sured at GD 0, 10 and 20. Non-fasting blood samples
were obtained via tail venipuncture, and serum glucose
level was determined by glucometer (Lifescan Surestep).
Plasma insulin levels were quantified by UltraSensitive
Mouse Insulin ELISA kit (ALPCO Diagnostics). Body
weight was measured on a top-loading balance (Fisher
Scientific).
Liver dissection
Livers were dissected using previously established method
[19]. On GD 10 after completing all other measurements,
6 out of 18 mice in each group were sacrificed to harvest
the liver, while the remaining 12 females were allowed
to complete pregnancy, and their offspring were also
sacrificed after birth to harvest the liver. Mice were anes-
thetized with 100 mg/kg ketamine, 10 mg/kg aceproma-
zine and 100 mg/kg xylazine. The abdominal cavity was
opened and the portal vein exposed. A bolus of insu-
lin (10 U/kg body weight in 100 μL saline) was injected
into the portal vein. The liver was immediately excised
and frozen at −80 °C until further analysis.
Immunoblot and antibodies
Protein samples were extracted from liver homogenates
in the presence of protease and phosphatase inhibitors.
Protein concentration was quantified by BCA assay sys-
tem (Bio-Rad, USA). Proteins were analyzed by 12 %
SDS-PAGE and transferred to nitrocellulose membrane
using semi-dry transfer unit (Bio-Rad). The membrane
was then immersed in blocking buffer (PBS, 0.1 %
Tween-20) with 5 % nonfat milk for 20 min and then in-
cubated with appropriate primary antibody (1:1000 dilu-
tion in blocking buffer) overnight at 4 °C. After washes
with blocking buffer, blots were incubated with appro-
priate HRP-conjugated secondary antibody (1:5000 dilu-
tion in blocking buffer; Life Technologies) for 20 min at
room temperature, washed again with blocking buffer,
and visualized using Luminata Forte Western HRP Sub-
strate (EMD Millipore). AMPK (#2532), phosphor-AMPK
(#2535), HDAC4 (#2072) and phosphor-HDAC4 (#3443)
antibodies were purchased from Cell Signaling. Glucose-
6-phosphatase (ab83690) and α-tubulin (ab125267) anti-
bodies were purchased from Abcam.
Liver glucose-6-phosphatase (G6Pase) activity
Microsomes were prepared from frozen liver samples as
previously described [19]. G6Pase activity was measured
on intact microsomes with 0.5, 2.5, and 10 mM of
glucose-6-phosphate (G6P) as previously described [19].
Total protein was determined by the Bradford method.
G6Pase activity was normalized by subtracting nonspe-
cific phosphatase activity, which was determined using
paranitrophenylphosphate.
Statistical analysis
All values were presented as mean ± SEM, with number
of independent experiments stated in respective figure
legends. Statistical significance was analyzed using two
tailed Student’s t-test between groups stated in respect-
ive figure legends. Differences were determined to be
statistically significant when P < 0.05.
Results
RV relieved glucose and insulin intolerance in pregnant
db/+ mice
We first examined the effect of RV in the non-pregnant
db/+ mice, which usually do not present diabetic symp-
toms as previously reported [19]. By employing a glucose
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tolerance test in all three groups of non-pregnant mice,
we confirmed that glucose and insulin levels were simi-
lar in wild type and pair-fed db/+ mice, and RV didn’t
cause any changes in either glucose or insulin levels
(Fig. 1b and c).
Next we performed the same glucose tolerance test in
all three groups of mice, during their pregnant state on
GD 10. We found that, compared with wild type, preg-
nant db/+ females exhibited prominent glucose intoler-
ance, as indicated by significantly elevated glucose levels
after the initial glucose injection (Fig. 1d, 30 and 60 min),
and RV treatment was able to largely alleviate this glucose
intolerance in the pair-fed db/+ mice. In the same experi-
ment, insulin levels of db/+ mice was significant lower
than that of wild type throughout the test (Fig. 1e, 0, 30
and 60 min), explaining the glucose intolerance pheno-
type. Importantly, RV administration restored insulin re-
sponse to an indiscernible level as the wild type control
mice.
Compared to glucose tolerance test, which assesses the
combined outcome of glucose disposal and insulin secre-
tion, the insulin tolerance test is a more direct measure-
ment on the ability of insulin to rapidly stimulate
glucose disposal [8]. Therefore we next performed an
acute insulin tolerance test on GD 10 in all three groups
of mice (Fig. 1f ). As expected, the pair-fed db/+ females
exhibited significantly higher blood glucose levels than
the wild type following the initial insulin injection, sug-
gesting insulin resistance phenotype. Notably RV admin-
istration markedly reduced glucose levels in the pair-fed
db/+ mice, to similar levels as the wild type. Taken to-
gether, the above results indicated that RV was able to
extenuate acute glucose and insulin intolerance in preg-
nant db/+ mice.
We also measured the steady state levels of blood glu-
cose and insulin levels throughout the pregnancy. We
found that blood glucose levels of wild type females
remained stable on GD 0, 10 and 20 (Fig. 2a). Whereas
meanwhile, db/+ females showed significantly elevated
blood glucose levels, indicating the typical hyperglycemia
symptom of GDM. However, blood glucose levels of db/+
females receiving RV stayed at the same as the wild type
group through the entire duration of pregnancy, indicating
the alleviating effect on hyperglycemia by RV. In a similar
manner, steady state insulin levels in db/+ mice were also
significantly lower than wild type, which could be fully re-
stored by RV administration (Fig. 2b). Maternal body
weight gains in all three groups of mice were almost the
same throughout the pregnancy (Fig. 2c).
RV increased liver AMPK activation in pregnant db/+ mice
As AMPK is likely to be a potential target of RV func-
tion in diabetes, we sacrificed 6 mice from each group at
GD 10 and harvested their livers for immunoblot analysis.
As shown in Fig. 3a, AMPK activation was found to be at-
tenuated in db/+ pair-fed mice, contributing to higher
HDAC4 activation, which in turn elevated G6Pase expres-
sion in the liver. Consistent with previous reports [15, 16],
RV administration fully reversed the trend of activation
profile of the related proteins, eventually reducing G6Pase
levels to almost the same as in wild type (Fig. 3b).
RV improved reproductive outcome of pregnant db/+ mice
One of the adverse effects of GDM is decreased fetal
survival, presented as fewer number of fetuses [20, 21].
Moreover in the same db/+ GDM mouse model, body
weight of offspring at birth was reported to increase by
5–8 % [7, 8]. Therefore we next investigated whether RV
was able to improve fetal development of GDM female
mice.
Offspring number at birth was counted for each fe-
males from wild type, db/+ pair-fed and db/+ pair-fed +
RV groups (Fig. 4a). The 12 wild type female mice gave
birth to 86 litters, whereas the 12 females from the db/+
pair-fed group gave birth to only 58 litters. In contrast,
82 litters were born by the 12 db/+ pair-fed + RV group
of females. Furthermore we recorded the body weight of
offspring at birth in the three groups (Fig. 4b), and found
that, consistent with previous reports [7, 8], mean body
weight of offspring born by db/+ pair-fed mothers was
Fig. 2 RV relieved GDM symptoms in pregnant db/+ mice. Serum glucose (a) and insulin levels (b), and maternal body weight (c) were measured
on gestation day (GD) 0, 10 and 20 in wild type, db/+ pair-fed and db/+ pair-fed + RV mice. Values represented mean ± SEM (n = 12). *P < 0.01,
#P < 0.05, db/+ pair-fed vs wild type and db/+ pair-fed + RV mice at the same time point
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significantly higher than those by wild type mothers,
whereas body weight of offspring from db/+ pair-fed +
RV group was almost the same as wild type control. Dif-
ferences in reproduction outcome among these groups
was not attributed to any specific GDM genetic condi-
tion of the fetus, since all of their offspring genotype
composition followed Mendelian ratio (Additional file 1:
Table S1). These results clearly indicated RV was able to
improve the reproductive outcome of GDM female
mice.
RV increased liver G6Pase activity in offspring of db/+ mice
We speculate the reason for the increased body weight
at birth of offspring from db/+ mice could also be attrib-
uted to elevated liver G6Pase. Therefore we chose 12
offspring from each group of female mice, with the same
genotype composition, and harvested their livers to assay
for G6Pase activity (Fig. 5). As expected, G6Pase activity
was significantly increased in the db/+ pair-fed offspring,
which could be reduced by RV administration in the db/+
pair-fed + RV offspring. This result clearly indicated that
RV also reduced the enzymatic capacity for glucose pro-
duction in the fetus, likely through enhancing AMPK acti-
vation (Fig. 3).
Discussion
GDM affects almost 10 % of pregnancies, and women
suffering from GDM have higher risk of long-term type-
2 diabetes [1]. Although increasing body of basic and
clinical researches have been conducted on diabetes,
very few of them were specifically tailored towards
GDM, which took the approach of dietary intervention
[22]. However, given the relative similar cause and symp-
toms between diabetes and GDM, substances such as
RV in our current study with beneficial effect on dia-
betes are highly likely to exhibit similar functions in alle-
viating GDM. Indeed out results demonstrated that RV
was able to significantly alleviate GDM symptoms such
Fig. 3 RV increased AMPK activation in pregnant db/+ mice. Representative immunoblot (a) and quantification (b) of phosphorylated(p)-AMPK,
total AMPK, pHDAC4, total HDAC4 and glucose-6-phosphatase (G6Pase) in pregnant mice liver on GD 10. Values represented mean ± SEM (n = 6).
*P < 0.01, #P < 0.05, db/+ pair-fed + RV vs db/+ pair-fed mice. ns not significant, db/+ pair-fed + RV vs wild type mice
Fig. 4 RV improved reproductive outcome of pregnant db/+ mice. Litter size (a) and body weight at birth (b) of offspring born by each female
mouse from wild type, db/+ pair-fed and db/+ pair-fed + RV experimental groups were recorded (n = 12). #P < 0.05, db/+ pair-fed + RV vs db/+
pair-fed mice. ns not significant, db/+ pair-fed + RV vs wild type mice
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as hyperglycemia, insulin resistance, decreased fetal sur-
vival and increased body weight at birth in the db/+ gen-
etic mouse model.
Although previous study has found that RV could pro-
tect chicken embryos from high-glucose-induced oxida-
tive stress and mal-development [23], our study is the
first of its kind to report that RV exhibited alleviating
functions in treating GDM in mammals. Furthermore,
we investigated into the underlying molecular mechan-
ism responsible for the observed effect of RV in GDM
mouse model. We found that RV could increase the acti-
vation of AMPK in the liver of pregnant db/+ mice, as
well as their offspring. Our findings points to the func-
tion of RV to activate AMPK, which is consistent with
previous report [24]. Moreover in mice deficient in
AMPK catalytic subunits, RV failed to alleviate diabetic
symptoms, further indicating the involvement of AMPK
in RV-mediated effects [25]. In the liver, AMPK activa-
tion regulates glucose production, in that it inhibits
HDACs, which in turn leads to down-regulated G6Pase
expression and activity [18]. Our current work, to-
gether with those by Guo et al. and O’Tierney-Ginn
et al. [15, 16], consistently pointed to the role of AMPK
in the regulation of diabetes and GDM. In this context,
AMPK could serve as a biomarker for the diagnosis and
treatment of diabetic symptoms, which also warrants
the search for other compounds that modulate AMPK
activation.
Another major adverse symptom of GDM is fetal mal-
development, which was reported in several studies
using rodent models [5, 7, 8, 20, 21]. Reduced offspring
number is one of the common phenotypes, as consist-
ently observed in our study as well. On the other hand,
diverse data on body weight of offspring at birth was ob-
served in different models, higher in mice whereas lower
in rats [26, 27]. These seemingly contradictory results
were likely caused by either dietary or species variations.
In our study the db/+ genetic GDM females were fed
with a diet higher in protein than standard diet [28],
which might be the one of the reasons that offspring
born by GDM mothers have nearly 10 % increase in
body weight at birth, compared with those born by wild
type mothers. Importantly, RV administration was able
to fully rescue this defect in fetal development in db/+
mice, likely through down-regulation of G6Pase activity
in fetal livers. In this context, our results to the potential
combination of a diet lower in protein content and RV
to further improve reproductive outcome of GDM mice,
at least in reducing the abnormally high body weight at
birth of offspring.
In conclusion, our current study provided the first in-
stance of using the natural compound RV as a thera-
peutic reagent to treat GDM in the db/+ mouse model.
RV administration significantly relieved hyperglycemia
and insulin resistance in pregnant db/+ female mice, as
well as improved fetal development and reproductive
outcome. Further analysis revealed that this effect of RV
was mediated by elevated AMPK activation, which in
turn inhibited HDAC4 phosphorylation, and eventually
down-regulated G6Pase expression and activity. Findings
in our study have further supported the potential thera-
peutic effect of RV in treating not only diabetes, but also
alleviating GDM symptoms.
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